RLYB Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -4576.89% compared to Rallybio Corp.'s net margin of --. Rallybio Corp.'s return on equity of -23.97% beat CEL-SCI Corp.'s return on equity of -266.61%.

Rallybio Corp. has a consensus price target of $1.00, signalling upside risk potential of 51.1%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Rallybio Corp., analysts believe CEL-SCI Corp. is more attractive than Rallybio Corp..

Rallybio Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Rallybio Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio Corp. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Rallybio Corp. quarterly revenues are $212K, which are larger than CEL-SCI Corp. quarterly revenues of --. Rallybio Corp.'s net income of $16M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Rallybio Corp.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio Corp. is 44.02x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -4576.89% compared to Rallybio Corp.'s net margin of -953.4%. Rallybio Corp.'s return on equity of -23.97% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Rallybio Corp. has a consensus price target of $1.00, signalling upside risk potential of 51.1%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Rallybio Corp., analysts believe IGC Pharma, Inc. is more attractive than Rallybio Corp..

Rallybio Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Rallybio Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio Corp. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Rallybio Corp. quarterly revenues are $212K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Rallybio Corp.'s net income of $16M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Rallybio Corp.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio Corp. is 44.02x versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -4576.89% compared to Rallybio Corp.'s net margin of -255.85%. Rallybio Corp.'s return on equity of -23.97% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Rallybio Corp. has a consensus price target of $1.00, signalling upside risk potential of 51.1%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Rallybio Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Rallybio Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Rallybio Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Rallybio Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Rallybio Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rallybio Corp. quarterly revenues are $212K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Rallybio Corp.'s net income of $16M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Rallybio Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio Corp. is 44.02x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -4576.89% compared to Rallybio Corp.'s net margin of -3135.32%. Rallybio Corp.'s return on equity of -23.97% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Rallybio Corp. has a consensus price target of $1.00, signalling upside risk potential of 51.1%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 34.47%. Given that Rallybio Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Rallybio Corp. is more attractive than Recursion Pharmaceuticals, Inc..

Rallybio Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rallybio Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rallybio Corp. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rallybio Corp. quarterly revenues are $212K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Rallybio Corp.'s net income of $16M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Rallybio Corp.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rallybio Corp. is 44.02x versus 43.21x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.